AFMD:NSD-Affimed N.V (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.34

Change

-0.05 (-0.78)%

Market Cap

USD 0.78B

Volume

0.57M

Avg Analyst Target

USD 15.00 (+136.59%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

USD21.89B N/A N/A

ETFs Containing AFMD

Symbol Name Weight Mer Price(Change) Market Cap
AIIQ AI Powered International .. 0.00 % 0.79 %

+0.09 (+0.27%)

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.93% 69% D+ 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.93% 69% D+ 54% F
Trailing 12 Months  
Capital Gain 91.54% 83% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.54% 83% B 79% C+
Trailing 5 Years  
Capital Gain 115.65% 75% C 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.65% 75% C 72% C-
Average Annual (5 Year Horizon)  
Capital Gain 52.32% 75% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.32% 75% C 85% B
Risk Return Profile  
Volatility (Standard Deviation) 93.32% 31% F 18% F
Risk Adjusted Return 56.07% 83% B 73% C
Market Capitalization 0.78B 68% D+ 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.29 44% F 34% F
Price / Cash Flow Ratio -40.00 87% B+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.90% 68% D+ 32% F
Return on Invested Capital -61.25% 39% F 14% F
Return on Assets -12.51% 80% B- 26% F
Debt to Equity Ratio 0.32% 83% B 90% A-
Technical Ratios  
Short Ratio 3.81 57% F 44% F
Short Percent 3.64% 64% D 44% F
Beta 2.65 5% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.